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VARIABILITY IN THE CRITERIA FOR EARLY 
SWITCH AND EARLY DISCHARGE IN 
COMMUNITY-ACQUIRED PNEUMONIA: A 
SYSTEMATIC REVIEW OF THE LITERATURE
Rhew DC1,2, Tu GS1, Ofman J1, Henning JM3, Richards MS3, 
Weingarten SR1
1Zynx Health Inc., Cedars-Sinai, Departments of Medicine and 
Health Services Research, Beverly Hills, CA, USA; 2West Los 
Angeles VA Medical Center, Los Angeles, CA, USA; 3TAP 
Holdings Inc., Deerfield, IL, USA
Strategies to achieve early switch from intravenous to
oral antibiotics and early discharge (ES
) for patients
with community-acquired pneumonia (CAP) are imple-
mented in an attempt to improve quality and efficiency of
care. A systematic review of ES
 criteria has not been
previously performed. OBJECTIVES: To assess differen-
tial features of ES
 criteria in the published literature.
METHODS: We searched MEDLINE, HEALTHSTAR,
EMBASE, COCHRANE COLLABORATION, and BEST
EVIDENCE databases from 1980–1999 for CAP studies
that included specific switch criteria or recommendations
to switch on a particular day. Explicit inclusion and ex-
clusion criteria were applied to titles, abstracts, and arti-
cles. Physician reviews were done in duplicate, with dis-
agreement resolved by consensus. RESULTS: From 3666
titles identified, 305 abstracts were reviewed. Of 85 arti-
cles selected, 62 (73%) were retrieved and reviewed. We
identified 12 prospective interventional CAP-specific stud-
ies. Switch criteria included: resolution of fever (67%),
improving respiratory signs and/or symptoms (50%),
ability to take oral medications (50%), normalization of
white blood cell count (33%), “clinical stability” (NOS)
(33%), minimal IV treatment (25%), hemodynamic sta-
bility (25%), no other sites of infection (25%), unaltered
mental status (17%), and stable or improving radio-
graphic findings (8%) (reviewer kappa, 1.0). Nine differ-
ent criteria combinations were applied in the 12 studies.
Four studies applied separate criteria for early discharge:
care for comorbid conditions (75%), need for diagnostic
work-up (25%), social needs (25%), and clinical stability
during observation (25%) (kappa  1.0). Three different
discharge criteria combinations were applied in 4 studies.
A specific post-switch antibiotic was recommended in 8
(67%) studies, specific day for switch (median, day 3) in
7 (58%) studies, and specific day for discharge (median,
day 4) in 4 (33%) studies. CONCLUSION: Systematic
review reveals that there is considerable variability in
ES
 criteria, which may promote uncertainty regarding
the interpretation of results from ES
 studies.
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COSTS AND OUTCOMES OF A RESPIRATORY 
SYNCYTIAL VIRUS PROPHYLAXIS PROGRAM IN 
A MEDICAID MANAGED CARE ORGANIZATION
Schaffer M, Amaya MA, Vojta D
Health Partners, Philadelphia, PA, USA
Respiratory Syncytial Virus (RSV) is a known cause of
morbidity in premature infants, as well as those with
bronchopulmonary dysplasia. OBJECTIVE: To measure
the impact of a RSV prophylaxis program on pulmonary-
related hospitalizations (PRH), average length-of-stay
(ALOS), and cost/immunized member to a Medicaid man-
aged care plan. METHODS: Through administrative claims
we identified members at risk for RSV infection based on
American Academy of Pediatrics (AAP) guidelines for
RSV prophylaxis. Baselines were determined for PRH
rate and ALOS for two seasons prior to intervention (N 
452). We identified 205 high-risk infants eligible for pro-
phylaxis. Physicians were mailed a list of their eligible
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(pre-authorized) members and AAP guidelines for palivi-
zumab prophylaxis. Physicians were asked to treat ac-
cording to clinical judgement. We then compared PRH,
ALOS, and costs (PRH, drug, and administration) be-
tween prophylaxed (N  69) and non-prophylaxed (N 
136) high-risk children. PRH were defined based on ICD-
9-CM discharge codes for RSV infection, bronchiolitis,
pneumonia, bronchitis, asthma, and other abnormal res-
piratory conditions. Hospitalization costs were tallied at
$1500/day. RESULTS: Overall PRH rate and ALOS
were reduced from 35.2% and 12.9 days in the baseline
period to 25.9% (P  0.1) and 8.1 days (P  0.05) re-
spectively. Non-prophylaxed children consumed more re-
sources (31.6% PRH, 8.7 ALOS) than prophylaxed chil-
dren (14.5% PRH, 5.4 ALOS). Reductions from baseline
PRH and ALOS were significant in the treatment group
(P  0.05 for each). Drug and administration costs of
$286,725 saved $467,571 in expected costs had baseline
rates continued ($2281/high-risk member, $6776/immu-
nized member). CONCLUSIONS: Guideline dissemina-
tion and pre-authorizing RSV prophylaxis with palivi-
zumab in a high-risk Medicaid population is an effective
policy tool for reduction of associated PRH, ALOS, as
well as costs.
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OUTCOMES AND COSTS OF ACUTE MYELOID 
LEUKEMIA OVER ONE YEAR FOLLOWING 
DIAGNOSIS: AN ANALYSIS OF 
SEER-MEDICARE DATA
Menzin J1, Lang K1, Earle CE2, Kerney D1
1Boston Health Economics, Inc., Billerica, MA, USA; 2Harvard 
Medical School, Boston, MA, USA
The incidence of acute myeloid leukemia (AML) is grow-
ing among the elderly. However, data on the clinical out-
comes and costs of this form of cancer are sparse. OB-
JECTIVE: To estimate rates of mortality and hospitalization
costs in the first year following the diagnosis of AML
among US Medicare beneficiaries 65 years of age and
older. METHODS: This study was based on SEER-Medi-
care data files, which include a linkage between cancer
registry data and Medicare administrative claims data for
approximately 14% of cancer cases identified in 17 geo-
graphically diverse regions across the US. Patients ini-
tially diagnosed with AML between 1991 and 1993 were
identified from SEER registry data and followed for one
year. The use of chemotherapy was ascertained based on
DRGs, and ICD-9-CM diagnosis and procedure codes.
Costs of care were based on total Medicare hospital pay-
ments. RESULTS: A total of 1,391 patients with AML
were identified. In the year following diagnosis, only
27% of these patients underwent chemotherapy treat-
ment. The prognosis for AML was quite poor, with a me-
dian survival estimated to be 3 months (mean  SD: 5.2 
5.1), and over 75% of patients having died within one
year. The number of hospitalizations (mean  SD) dur-
ing the one-year follow-up was 1.95  1.50, with corre-
sponding Medicare inpatient payments of $23,670 
$26,583. Average Medicare hospital payments varied
only slightly by sex and race, and declined substantially
by age (due to poorer survival). Patients who underwent
chemotherapy had costs almost 3 times higher than those
of other patients, but also lived an average of 3 months
longer. CONCLUSION: AML among the elderly is asso-
ciated not only with a poor prognosis, but also with sub-
stantial inpatient costs over the relatively few remaining
months of life.
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